Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Clofibrate | The risk or severity of adverse effects can be increased when Clofibrate is combined with Aluminium clofibrate. |
| Fenofibrate | The risk or severity of adverse effects can be increased when Fenofibrate is combined with Aluminium clofibrate. |
| Gemfibrozil | The risk or severity of adverse effects can be increased when Gemfibrozil is combined with Aluminium clofibrate. |
| Bezafibrate | The risk or severity of adverse effects can be increased when Bezafibrate is combined with Aluminium clofibrate. |
| Etofibrate | The risk or severity of adverse effects can be increased when Etofibrate is combined with Aluminium clofibrate. |
| Ciprofibrate | The risk or severity of adverse effects can be increased when Ciprofibrate is combined with Aluminium clofibrate. |
| Simfibrate | The risk or severity of adverse effects can be increased when Simfibrate is combined with Aluminium clofibrate. |
| Ronifibrate | The risk or severity of adverse effects can be increased when Ronifibrate is combined with Aluminium clofibrate. |
| Clofibride | The risk or severity of adverse effects can be increased when Aluminium clofibrate is combined with Clofibride. |
| Fenofibric acid | The risk or severity of adverse effects can be increased when Aluminium clofibrate is combined with Fenofibric acid. |
| Ezetimibe | The serum concentration of Ezetimibe can be increased when it is combined with Aluminium clofibrate. |
| Glycochenodeoxycholic Acid | The therapeutic efficacy of Glycochenodeoxycholic Acid can be decreased when used in combination with Aluminium clofibrate. |
| Cholic Acid | The therapeutic efficacy of Cholic Acid can be decreased when used in combination with Aluminium clofibrate. |
| Glycocholic acid | The therapeutic efficacy of Glycocholic acid can be decreased when used in combination with Aluminium clofibrate. |
| Deoxycholic acid | The therapeutic efficacy of Deoxycholic acid can be decreased when used in combination with Aluminium clofibrate. |
| Taurocholic acid | The therapeutic efficacy of Taurocholic acid can be decreased when used in combination with Aluminium clofibrate. |
| Obeticholic acid | The therapeutic efficacy of Obeticholic acid can be decreased when used in combination with Aluminium clofibrate. |
| Chenodeoxycholic acid | The therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Aluminium clofibrate. |
| Taurochenodeoxycholic acid | The therapeutic efficacy of Taurochenodeoxycholic acid can be decreased when used in combination with Aluminium clofibrate. |
| Tauroursodeoxycholic acid | The therapeutic efficacy of Tauroursodeoxycholic acid can be decreased when used in combination with Aluminium clofibrate. |
| Bamet-UD2 | The therapeutic efficacy of Bamet-UD2 can be decreased when used in combination with Aluminium clofibrate. |
| Dehydrocholic acid | The therapeutic efficacy of Dehydrocholic acid can be decreased when used in combination with Aluminium clofibrate. |
| Hyodeoxycholic Acid | The therapeutic efficacy of Hyodeoxycholic Acid can be decreased when used in combination with Aluminium clofibrate. |
| Ursodeoxycholic acid | The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Aluminium clofibrate. |
| Cyclosporine | The risk or severity of renal failure can be increased when Cyclosporine is combined with Aluminium clofibrate. |
| Glimepiride | The risk or severity of hypoglycemia can be increased when Aluminium clofibrate is combined with Glimepiride. |
| Acetohexamide | The risk or severity of hypoglycemia can be increased when Aluminium clofibrate is combined with Acetohexamide. |
| Chlorpropamide | The risk or severity of hypoglycemia can be increased when Aluminium clofibrate is combined with Chlorpropamide. |
| Tolazamide | The risk or severity of hypoglycemia can be increased when Aluminium clofibrate is combined with Tolazamide. |
| Glyburide | The risk or severity of hypoglycemia can be increased when Aluminium clofibrate is combined with Glyburide. |
| Glipizide | The risk or severity of hypoglycemia can be increased when Aluminium clofibrate is combined with Glipizide. |
| Gliclazide | The risk or severity of hypoglycemia can be increased when Aluminium clofibrate is combined with Gliclazide. |
| Tolbutamide | The risk or severity of hypoglycemia can be increased when Aluminium clofibrate is combined with Tolbutamide. |
| Gliquidone | The risk or severity of hypoglycemia can be increased when Aluminium clofibrate is combined with Gliquidone. |
| Glisoxepide | The risk or severity of hypoglycemia can be increased when Aluminium clofibrate is combined with Glisoxepide. |
| Glibornuride | The risk or severity of hypoglycemia can be increased when Aluminium clofibrate is combined with Glibornuride. |
| Carbutamide | The risk or severity of hypoglycemia can be increased when Aluminium clofibrate is combined with Carbutamide. |
| Metahexamide | The risk or severity of hypoglycemia can be increased when Aluminium clofibrate is combined with Metahexamide. |
| Colestipol | Colestipol can cause a decrease in the absorption of Aluminium clofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sevelamer | Sevelamer can cause a decrease in the absorption of Aluminium clofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Colesevelam | Colesevelam can cause a decrease in the absorption of Aluminium clofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cholestyramine | Cholestyramine can cause a decrease in the absorption of Aluminium clofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dicoumarol | The risk or severity of bleeding can be increased when Aluminium clofibrate is combined with Dicoumarol. |
| Phenindione | The risk or severity of bleeding can be increased when Aluminium clofibrate is combined with Phenindione. |
| Warfarin | The risk or severity of bleeding can be increased when Aluminium clofibrate is combined with Warfarin. |
| Phenprocoumon | The risk or severity of bleeding can be increased when Aluminium clofibrate is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of bleeding can be increased when Aluminium clofibrate is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of bleeding can be increased when Aluminium clofibrate is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of bleeding can be increased when Aluminium clofibrate is combined with Coumarin. |
| (R)-warfarin | The risk or severity of bleeding can be increased when Aluminium clofibrate is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of bleeding can be increased when Aluminium clofibrate is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of bleeding can be increased when Aluminium clofibrate is combined with Fluindione. |
| Clorindione | The risk or severity of bleeding can be increased when Aluminium clofibrate is combined with Clorindione. |
| Diphenadione | The risk or severity of bleeding can be increased when Aluminium clofibrate is combined with Diphenadione. |
| Tioclomarol | The risk or severity of bleeding can be increased when Aluminium clofibrate is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of bleeding can be increased when Aluminium clofibrate is combined with (S)-Warfarin. |
| Tacrolimus | Tacrolimus may increase the nephrotoxic activities of Aluminium clofibrate. |
| Pravastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Aluminium clofibrate is combined with Pravastatin. |
| Lovastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Aluminium clofibrate is combined with Lovastatin. |
| Cerivastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Aluminium clofibrate is combined with Cerivastatin. |
| Simvastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Aluminium clofibrate is combined with Simvastatin. |
| Atorvastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Aluminium clofibrate is combined with Atorvastatin. |
| Fluvastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Aluminium clofibrate is combined with Fluvastatin. |
| Rosuvastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Aluminium clofibrate is combined with Rosuvastatin. |
| Mevastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Aluminium clofibrate is combined with Mevastatin. |
| Pitavastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Aluminium clofibrate is combined with Pitavastatin. |
| Leuprolide | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Aluminium clofibrate. |
| Somatotropin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Aluminium clofibrate. |
| Infliximab | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Aluminium clofibrate. |
| Daptomycin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Aluminium clofibrate. |
| Baclofen | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Baclofen is combined with Aluminium clofibrate. |
| Sildenafil | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sildenafil is combined with Aluminium clofibrate. |
| Indinavir | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Indinavir is combined with Aluminium clofibrate. |
| Cladribine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Aluminium clofibrate. |
| Phenytoin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Phenytoin is combined with Aluminium clofibrate. |
| Pamidronic acid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Aluminium clofibrate. |
| Mefloquine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Mefloquine is combined with Aluminium clofibrate. |
| Tacrine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrine is combined with Aluminium clofibrate. |
| Carbimazole | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Aluminium clofibrate. |
| Trimethoprim | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Aluminium clofibrate. |
| Betamethasone | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Betamethasone is combined with Aluminium clofibrate. |
| Montelukast | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Montelukast is combined with Aluminium clofibrate. |
| Zidovudine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Zidovudine is combined with Aluminium clofibrate. |
| Cimetidine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Aluminium clofibrate. |
| Ritonavir | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Aluminium clofibrate. |
| Lercanidipine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Aluminium clofibrate. |
| Ciprofloxacin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Aluminium clofibrate. |
| Vincristine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Aluminium clofibrate. |
| Propylthiouracil | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Aluminium clofibrate. |
| Methotrexate | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Methotrexate is combined with Aluminium clofibrate. |
| Enalapril | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Enalapril is combined with Aluminium clofibrate. |
| Nizatidine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nizatidine is combined with Aluminium clofibrate. |
| Ivermectin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ivermectin is combined with Aluminium clofibrate. |
| Chloroquine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Chloroquine is combined with Aluminium clofibrate. |
| Triamcinolone | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triamcinolone is combined with Aluminium clofibrate. |
| Niacin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Niacin is combined with Aluminium clofibrate. |
| Alendronic acid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Aluminium clofibrate. |
| Stavudine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Stavudine is combined with Aluminium clofibrate. |
| Nafarelin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nafarelin is combined with Aluminium clofibrate. |
| Amphotericin B | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Aluminium clofibrate. |